By Iqra Sharjeel
The pharmaceutical industry has given the world countless life-saving medications — from antibiotics and insulin to cancer therapies and vaccines. But behind the scenes of innovation lies a growing controversy that refuses to be ignored:
Are pharmaceutical companies putting profits before people’s health?
This question has become a flashpoint for patients, healthcare professionals, activists, and even governments across the world. At the heart of the debate is one critical issue — drug pricing.
Why Are Life-Saving Drugs So Expensive?
For decades, pharmaceutical companies have defended high drug prices by pointing to research and development (R&D) costs. They argue that developing a new drug takes billions of dollars and over a decade of trials, failures, and regulatory approval. While this is partly true, studies have shown that in many cases, drug prices are marked up far beyond the actual cost of production and R&D — especially in countries without price control regulations.
Take insulin, for example. Discovered over a century ago, insulin is essential for millions of diabetics worldwide. Yet in some countries like the U.S., the price has skyrocketed by over 1,000% in the past two decades, making it unaffordable for many. This has led to tragic stories of patients rationing insulin or dying because they couldn’t afford their next dose.
Patents, Power, and Monopoly
A major source of controversy lies in the way pharmaceutical companies use patent laws to maintain monopolies. When a company patents a drug, no other manufacturer can sell a generic version for years. While this exclusivity is meant to encourage innovation, many companies exploit it through “evergreening” — making minor changes to a drug to extend patent life and block competition.
This strategy often delays the release of cheaper generic alternatives, keeping prices high and access limited, especially in low- and middle-income countries. Meanwhile, profits soar. In 2023 alone, several top pharmaceutical companies reported record-breaking earnings, with billions spent not on R&D, but on marketing, lobbying, and shareholder dividends.
Ethics vs. Business: Where’s the Line?
Pharmaceutical giants argue they operate within the boundaries of capitalism — and that profits are essential to fund innovation. But public health advocates ask:
Should health and life be governed by market forces?
It’s a moral dilemma. Should cancer treatments cost $100,000+ per year? Should a patient die because they can’t afford a pill that costs less than $10 to produce?
The COVID-19 pandemic magnified these questions. Despite billions in public funding for vaccine development, companies were accused of profiteering during a global crisis, prioritizing wealthy nations and failing to share technology with poorer countries.
The Call for Change
Patients, doctors, and even some policymakers are now demanding reforms:
- Transparent drug pricing models
- Patent law reform to prevent abuse
- Government-funded R&D to reduce industry monopoly
- Global access initiatives to ensure life-saving medicines are affordable worldwide
Countries like India, Brazil, and South Africa have challenged the system by producing affordable generics for critical medications, sometimes clashing with big pharma in international courts.
Final Thought: Innovation Must Serve Humanity
No one denies that pharmaceutical companies have changed the world for the better. But when the drive for shareholder profit overshadows patient care, something is fundamentally wrong. We must find a balance where innovation is rewarded — but not at the cost of human lives.
Health is a human right, not a luxury item. It’s time to ask hard questions, demand transparency, and ensure that the business of saving lives doesn’t become a business of withholding them.
—
This has been an honest look at a tough truth — from #sapere. Stay aware. Stay informed. Stay human.
You must be logged in to post a comment.